日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Several factors that predict the outcome of large B-cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T-cell therapy can be identified before cell administration

在进行嵌合抗原受体(CAR)T细胞治疗前,可以识别出几个预测大B细胞淋巴瘤患者在接受CAR-T细胞治疗后复发/进展预后的因素。

Sýkorová, Alice; Folber, František; Polgárová, Kamila; Móciková, Heidi; Ďuraš, Juraj; Steinerová, Kateřina; Obr, Aleš; Heindorfer, Adriana; Ladická, Miriam; Lukáčová, Ľubica; Čellárová, Erika; Plameňová, Ivana; Belada, David; Janíková, Andrea; Trněný, Marek; Jančárková, Tereza; Procházka, Vít; Vranovský, Andrej; Králiková, Margaréta; Vydra, Jan; Smolej, Lukáš; Drgoňa, Ľuboš; Sedmina, Martin; Čermáková, Eva; Pytlík, Robert

Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies

捷克共和国单克隆丙种球蛋白病登记处的数据:冒烟型多发性骨髓瘤风险分层患者的临床特征和结局

Sandecka, Viera; Popkova, Tereza; Stork, Martin; Maisnar, Vladimir; Minarik, Jiri; Jungova, Alexandra; Pavlicek, Petr; Stejskal, Lukas; Pospisilova, Lenka; Heindorfer, Adriana; Obernauerova, Jarmila; Gregora, Evzen; Sykora, Michal; Ullrychova, Jana; Wrobel, Marek; Kessler, Petr; Jelinek, Tomas; Kunovszki, Peter; Bathija, Sacheeta; Gros, Blanca; Wilbertz, Sabine; Cai, Qian; Lam, Annette; Spicka, Ivan

OAB-046: COVID-19 infection in multiple myeloma patients – retrospective analysis of 371 Czech patients

OAB-046:多发性骨髓瘤患者的 COVID-19 感染——371 名捷克患者的回顾性分析

Mreiwed, Ghaida; MacInnes, Katherine C; Chen, Luke Y C; Trottier, Amy M; Philip, Chepsy C; Selvarajan, Sushil; Nayak, Lingaraj; Jain, Hasmukh; Kulkarni, Uday Prakash; Samuel, Prasanna; Agrawal, Narendra; Kayal, Smita; Mishra, Kundan; S, Pavitra D; Das, Smita; PK, Jayachandran; Bala, Stalin Chowdary; Raghavan, Vineetha; Paul, Mobin; Singh, Jagdeep; Mehta, Prashant; Vasudevan, Sreeraj; Majumdar, Swaratika; Nayak, Akshatha; Prakash, Om; S, Marimuthu; Rajendra, Akhil; Thorat, Jayashree; Bagal, Bhausaheb; Abraham, Aby; Bhurani, Dinesh; Ganesan, Prasanth; Sengar, Manju; Mathews, Vikram; Radocha, Jakub; Špička, Ivan; Pour, Luděk; Jelinek, Tomas; Jungova, Alexandra; Minarik, Jiri; Heindorfer, Adriana; Stejskal, Lukas; Ullrychova, Jana; Obernauerova, Jarmila; Kessler, Petr; Wrobel, Marek; Pavlíček, Petr; Sykora, Michal; Mikula, Peter; Maisnar, Vladimir; Hájek, Roman

Survival benefit of ixazomib, lenalidomide and dexamethasone (IRD) over lenalidomide and dexamethasone (Rd) in relapsed and refractory multiple myeloma patients in routine clinical practice

在常规临床实践中,伊沙佐米、来那度胺和地塞米松(IRD)方案较来那度胺和地塞米松(Rd)方案在复发/难治性多发性骨髓瘤患者中具有生存获益。

Minarik, Jiri; Pika, Tomas; Radocha, Jakub; Jungova, Alexandra; Straub, Jan; Jelinek, Tomas; Pour, Ludek; Pavlicek, Petr; Mistrik, Martin; Brozova, Lucie; Krhovska, Petra; Machalkova, Katerina; Jindra, Pavel; Spicka, Ivan; Plonkova, Hana; Stork, Martin; Bacovsky, Jaroslav; Capkova, Lenka; Sykora, Michal; Kessler, Petr; Stejskal, Lukas; Heindorfer, Adriana; Ullrychova, Jana; Skacel, Tomas; Maisnar, Vladimir; Hajek, Roman